Cambridge Heart Inc. (OTC:CAMH) is touting the results of another study its says shows the ability of its microvolt T-wave alternans test to predict arrhythmia and sudden death from heart attack.
The Billerica, Mass.-based firm said a clinical trial conducted at Jolimont Hospital in Haine Saint Paul, Belgium, followed 73 patients over a mean follow-up time of 39 months. During that time patients who showed an abnormal MTWA result were 7.6 times more likely to experience arrhythmia and 4.8 times more likely to die from a sudden cardiac event.
Cambridge Heart said the data was presented at the 9th Annual Scientific Meeting of the Belgian Society of Cardiology in Brussels. In March 2009 the company said a meta analysis of 13 clinical studies involving 6,000 heart patients showed that the test is an accurate predictor of the risk of heart disease.